从百亿估值到破产清算,斯微生物遭遇资金困境、实验停滞双重承压,国产mRNA疫苗三剑客走向没落?

华夏时报
18 Oct 2024

全文2773字,阅读约需8分钟,帮我划重点划重点01曾被估值百亿的国产mRNA疫苗明星公司斯微生物,因无力偿还前期裁决中的劳动仲裁款项以及其他债务,正式进入破产程序。02斯微生物创始人李航文目前人在国外,有可能带走了公章,公司暂无财产可供执行此前的判决。03由于资金困境和实验停滞,国产mRNA疫苗三剑客——斯微生物、艾博生物和丽凡达生物走向没落。04然而,业内认为三剑客走向没落的原因包括产品迟迟...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10